Source: Google NewsPublished on 2022-06-22
Related Articles:
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease | Small Molecules | News Channels - PipelineReview.com June 23, 2022 Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease | Small Molecules | News Channels PipelineReview.com
- Monthly research review – April 2021 April 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during April 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Athira Pharma (ATHA) Reports Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton - StreetInsider.com June 22, 2022 Athira Pharma (ATHA) Reports Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton StreetInsider.com
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
- Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease at the 2022 AD/PD™ Congress - GlobeNewswire March 20, 2022 Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease at the 2022 AD/PD™ Congress GlobeNewswire
- Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer's Disease at AD/PD™ 2022 Congress - GlobeNewswire March 14, 2022 Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer's Disease at AD/PD™ 2022 Congress GlobeNewswire
- Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer's Disease - GlobeNewswire May 9, 2022 Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer's Disease GlobeNewswire
- Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer's Disease - BioSpace May 9, 2022 Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer's Disease BioSpace
- EJS-ACT PD June 26, 2021 # # # # This week an announcement was made regarding The Edmond J. Safra Accelerating Clinical Treatments for Parkinson’s Disease (EJS-ACT PD) Initiative. It is hoping to revolutionise the way clinical trials for potentially disease-modifying drugs for Parkinson’s are conducted. The project is focused on the setting up a multi-arm, multi-stage (MAMS) platform for evaluating new therapies for PD.…
- Parkinson's Disease News - Editor's Picks (Archive 2016.09) October 15, 2016 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed ‘The Terrorist Inside My Husband’s Brain’: Robin Williams’ Widow Details His Disease – Live ScienceLive Science'The Terrorist Inside My Husband's Brain': Robin Williams' Widow Details His DiseaseLive ScienceBut Robin Williams was not diagnosed with Lewy body disease…
- Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton ... - KULR-TV March 14, 2022 Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton ... KULR-TV
- Monthly Research Review – October 2021 October 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American ... - KULR-TV March 2, 2022 Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American ... KULR-TV
- Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American ... - The Bakersfield Californian March 2, 2022 Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American ... The Bakersfield Californian
- Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting - GlobeNewswire March 2, 2022 Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting GlobeNewswire
- Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…